Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Endocrinology | Family Medicine | Internal Medicine | Pediatrics | Journal

Back to Journal Articles

U.K. Initiative Has Unclear Effects on Diabetes Care

Last Updated: May 27, 2009.

 

The quality and outcomes framework introduced in 2004 may have had detrimental effects

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Since the late 1990s, the management of diabetes has improved in the United Kingdom, but it may not be a direct result of the quality and outcomes framework introduced in 2004, according to a study published online May 27 in BMJ.

WEDNESDAY, May 27 (HealthDay News) -- Since the late 1990s, the management of diabetes has improved in the United Kingdom, but it may not be a direct result of the quality and outcomes framework introduced in 2004, according to a study published online May 27 in BMJ.

Melanie Calvert, Ph.D., of the University of Birmingham in the United Kingdom, and colleagues analyzed data from 147 general practices to compare annual diabetes prevalence and achievement of process and clinical outcomes during the three-year periods before and after introduction of the quality and outcomes framework.

Although process and clinical outcome measures improved during all six years, the researchers found that improvements in control of blood sugar, cholesterol, and blood pressure slowed after introduction of the quality and outcomes framework, especially in the up to two-thirds of patients with type 1 diabetes and one-third of patients with type 2 diabetes who did not meet the new diagnostic case definition. They also found that the quality and outcomes framework was not associated with improved management of type 1 diabetes or a decline in HbA1c levels above 10 percent among type 2 diabetics.

"Pay for performance may have contributed to the improvement in diabetes care but the relative importance of the quality and outcomes framework to other national quality improvement strategies is unclear," the authors write. "Our work and that of others highlights the potential unintended consequences of the scheme."

This study was sponsored by Pfizer; four authors reported financial relationships with several companies that manufacture therapies for diabetes.

Abstract
Full Text

Copyright © 2009 ScoutNews, LLC. All rights reserved.


Previous: Tamoxifen Recommended to Reduce Breast Cancer Risk Next: Gene Finding May Influence Kidney Transplant Outcomes

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2013
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.